Patients With mHSPC Need Different Approaches—1 in 2 Will Progress to mCRPC Within ~20 Months^1,*

Patients with metastatic hormone-sensitive prostate cancer (mHSPC) may progress as fast as ~20 months.¹

What Is the Unmet Need in Treating mHSPC?

mHSPC unmet need patient living with metastatic prostate cancer — Not an actual patient.

High-volume disease progresses 2x faster than low volume (10.9 months vs 22.4 months)^2,†
Low-volume, de novo disease progresses ~1.8x faster than recurrent (18.8 months vs 33.5 months)^2,†
~1 in 3 patients on ADT + ARPI alone do not reach undetectable PSA levels^3,‡

ADT, androgen deprivation therapy; ARPI, androgen receptor pathway inhibitor; mCRPC, metastatic castration-resistant prostate cancer; PSA, prostate-specific antigen.

*Represents retrospective data from a global analysis of 2859 patients with mCRPC, including how quickly and from which disease setting they progressed to mCRPC after treatment with hormonal therapy, chemotherapy, and bone-targeted agents.¹
^†Represents data from an observational analysis in real-world US clinical practices of 847 patients with mHSPC, all of whom received ARPI-based therapy in the mHSPC setting.²
^‡Represents data from a phase 3 study of ADT + ARPI (n=574) vs ADT alone (n=576).³

PLUVICTO Benefits in mAPMN/S PC (mHSPC)

Choose PLUVICTO + ARPI: The first and only therapy to deliver benefit vs ARPI in a broad (PSMA+) mHSPC population⁴

PLUVICTO targets PSMA, a biomarker overexpressed in more than 80% of men with prostate cancer^4-6

PLUVICTO provided longer life without progression^4,7

Primary analysis: PLUVICTO + ARPI reduced the risk of radiographic progression or death by 28% vs ARPI (HR=0.72 [95% CI, 0.58-0.90]; P=0.002)⁴
Final analysis: PLUVICTO + ARPI reduced the risk of radiographic progression or death by 33% vs ARPI (HR=0.67 [95% CI, 0.55-0.82])^7,*

PLUVICTO demonstrated a predictable safety profile⁴

Most common ARs (≥20%) in PSMA+ mHSPC: Fatigue, dry mouth, and nausea⁴

*Median rPFS was not reached in the PLUVICTO + ARPI arm vs 48.5 months (95% CI, 40.5-NE) in the ARPI arm. Final rPFS analysis was performed with a median follow-up period of 37.7 months vs the primary analysis at 23.6 months. This analysis was not controlled for Type-I error.^7,8

Identifying Right Patients for Early PSMA-Targeted Therapy

Medical oncologist Jahan Aghalar, MD, shares clinical perspectives on earlier use of PLUVICTO in PSMA‑positive mAPMN/S prostate cancer (mHSPC), using a patient case to highlight patient selection, early clinical decision‑making, and shared discussions.

With only one line of therapy to delay progression to mCRPC, how do you decide your approach?¹

See the data behind PLUVICTO

AR, adverse reaction; HR, hazard ratio; mAPMN/S PC, metastatic androgen pathway modulation-naive or -sensitive prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer; NE, not estimable; PSMA+, prostate-specific membrane antigen positive; rPFS, radiographic progression-free survival.

< Previous: Home

Next: mHSPC Patient Identification >

Patients With mHSPC Need Different Approaches—1 in 2 Will Progress to mCRPC Within ~20 Months^1,*

What Is the Unmet Need in Treating mHSPC?

Not an actual patient.

Choose PLUVICTO + ARPI: The first and only therapy to deliver benefit vs ARPI in a broad (PSMA+) mHSPC population⁴

Identifying Right Patients for Early PSMA-Targeted Therapy

With only one line of therapy to delay progression to mCRPC, how do you decide your approach?¹

IMPORTANT SAFETY INFORMATION

Indications

Patients With mHSPC Need Different Approaches—1 in 2 Will Progress to mCRPC Within ~20 Months1,*

What Is the Unmet Need in Treating mHSPC?

Not an actual patient.

Choose PLUVICTO + ARPI: The first and only therapy to deliver benefit vs ARPI in a broad (PSMA+) mHSPC population4

Identifying Right Patients for Early PSMA-Targeted Therapy

With only one line of therapy to delay progression to mCRPC, how do you decide your approach?1

Patients With mHSPC Need Different Approaches—1 in 2 Will Progress to mCRPC Within ~20 Months^1,*

Choose PLUVICTO + ARPI: The first and only therapy to deliver benefit vs ARPI in a broad (PSMA+) mHSPC population⁴

With only one line of therapy to delay progression to mCRPC, how do you decide your approach?¹